Showing 1 - 2 results of 2 for search 'Gayanie Ratnayake', query time: 0.01s Refine Results
  1. 1
    The antibody–drug conjugate targeting ROR1, NBE-002, is active in high-grade serous ovarian cancer preclinical models

    The antibody–drug conjugate targeting ROR1, NBE-002, is active in high-grade serous ovarian cancer preclinical models by Dongli Liu, Cassandra J. Vandenberg, Patrizia Sini, Lorenz Waldmeier, Rosa Baumgartinger, Laura Pisarsky, Georg Petroczi, Gayanie Ratnayake, Clare L. Scott, Caroline E. Ford

    Published 2025-04-01
    Get full text
    Article
    Save to List
    Saved in:
  2. 2
    Farletuzumab ecteribulin and MORAb‐109, folate receptor alpha and mesothelin targeting antibody–drug conjugates, show activity in poor prognosis gynaecological cancer models

    Farletuzumab ecteribulin and MORAb‐109, folate receptor alpha and mesothelin targeting antibody–drug conjugates, show activity in poor prognosis gynaecological cancer models by Ksenija Nesic, Katherine Rybinski, Gayanie Ratnayake, Gwo‐Yaw Ho, Ratana Lim, Marc Radke, Chloe Neagle, Elizabeth M. Swisher, Matthew J. Wakefield, Holly E. Barker, Keiji Furuuchi, Clare L. Scott, Cassandra J. Vandenberg

    Published 2025-03-01
    Get full text
    Article
    Save to List
    Saved in:

Search Tools: